Latest Neptune Technologies & Bioresources Inc (NEPT) Headlines
Neptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common Shares
PR Newswire - Thu Mar 06, 10:53AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.NTB), announced today that the syndicate of underwriters led by of Euro Pacific Canada Inc. and Roth Capital Partners, as Joint Book-Running Managers, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD) as Lead Manager, have exercised in full the over-allotment option to purchase an additional 1,500,000 common shares of Neptune at a price of US$2.50 per common share in connection with Neptune's previously announced public offering, completed on March 5, 2014. As a result of the exercise of the over-allotment option, Neptune received additional gross proceeds of US$3.75 million for total gross proceeds of US$28.75 million.
Neptune Announces Closing of US$25.0 Million Underwritten Offering of Common Shares
CNW Group - Wed Mar 05, 8:11AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today the closing of its previously announced public offering of 10,000,000 common shares at US$2.50 per common share for gross proceeds of US$25.0 million. Euro Pacific Canada Inc. and Roth Capital Partners, LLC acted as Joint Book-Running Managers for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as Lead Manager.
Neptune Announces Pricing of US$25 Million Offering of Common Shares
GlobeNewswire - Fri Feb 28, 7:34AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (Nasdaq:NEPT) (TSX:NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has priced an underwritten public offering of 10,000,000 newly issued common shares at a public offering price of US$2.50 per share.
Neptune Announces Proposed Offering of Common Shares
CNW Group - Thu Feb 27, 3:59PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission ("SEC") and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering.
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Neptune Appoints John Moretz as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Tue Feb 18, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces the appointment of John Moretz as special advisor to its Board of Directors. Mr. Moretz has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholders approval.
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
AFET Ends Seed Banking Empowerment for Farmers
by Ebrima Bah - All Africa Global Media - Wed Jan 15, 8:02AM CST
The Association of Farmers, Educators and Traders (AFET) and Fandema has ended a twenty-day workshop on leadership and good governance for cooperative members and managers of certified seed growers in the provincial parts of The Gambia.
Neptune Reports Third Quarter Results and Provides Update on Action Plan to Resume Operations
GlobeNewswire - Tue Jan 14, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces its consolidated financial results for the three and nine-month periods ended November 30, 2013 and provides update on action plan to resume operations.
Neptune Receives New Food Raw Material Certification in China
GlobeNewswire - Thu Jan 09, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces that it has received "New Food Raw Material" certification in China. Neptune is now able to sell its krill oil nutraceutical products in China, including its premium krill oil, NKO, as well as its Eco krill oil "EKO(TM)". No quality or safety concerns were found by China's National Health and Family Planning Commission, which attests to the strength of Neptune's products.
Antelope Audio Zodiac Platinum DSD DAC/Headphone Amp Debuts at CES, Setting New Standard for Accuracy, Transparency, Imaging and Dynamics
PR Newswire - Tue Jan 07, 11:00AM CST
Leading digital audio manufacturer Antelope Audio [CES: Venetian, suite 29-227] introduces its new Zodiac Platinum DSD DAC/headphone amplifier during the 2014 Consumer Electronics Show (CES) in Las Vegas. The Zodiac Platinum, features a unique 256X upsampling mode where DSD64 and DSD128 are upsampled to DSD256, thereby releasing the true potential of DSD - delivering new standards in accuracy, transparency, imaging, and dynamics. The new DSD DAC ships with an entirely new, second-generation Voltikus power supply and an elegant aluminum remote control.
Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 07, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) will be holding a conference call on Wednesday January 15, at 9:00 am ET to present its results for the third quarter ended November 30, 2013. The Company will also be providing an update on the status of its previously disclosed action plan to resume operations and supply customers.
Neptune Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently.
Neptune, Acasti and Enzymotec Sign Settlement Term Sheet Resulting in Stay of ITC Investigation for 30 Days
GlobeNewswire - Wed Dec 18, 7:59AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that on December 16, 2013, the Administrative Law Judge presiding over the pending International Trade Commission (ITC) Investigation involving Neptune and Acasti; and Enzymotec Ltd., and Enzymotec USA, Inc. (collectively, "Enzymotec") granted the parties' joint motion to stay the proceedings for thirty days. The investigation was instituted earlier this year by Neptune and Acasti in a complaint filed with the ITC alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players.
Enzymotec Ltd. Announces Signing of Settlement Term Sheet
GlobeNewswire - Wed Dec 18, 7:01AM CST
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec"), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced today that it signed a term sheet on December 16, 2013 with Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) ("Neptune") and Acasti Pharma Inc. ("Acasti") memorializing the terms of a settlement among the parties. The term sheet is confidential and the settlement is subject to negotiation and execution of a final written settlement agreement. The on-going U.S. International Trade Commission ("ITC") investigation brought against Enzymotec by Neptune and Acasti has been stayed.
Neptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common Shares
PR Newswire - Thu Mar 06, 10:53AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.NTB), announced today that the syndicate of underwriters led by of Euro Pacific Canada Inc. and Roth Capital Partners, as Joint Book-Running Managers, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD) as Lead Manager, have exercised in full the over-allotment option to purchase an additional 1,500,000 common shares of Neptune at a price of US$2.50 per common share in connection with Neptune's previously announced public offering, completed on March 5, 2014. As a result of the exercise of the over-allotment option, Neptune received additional gross proceeds of US$3.75 million for total gross proceeds of US$28.75 million.
Neptune Announces Closing of US$25.0 Million Underwritten Offering of Common Shares
CNW Group - Wed Mar 05, 8:11AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today the closing of its previously announced public offering of 10,000,000 common shares at US$2.50 per common share for gross proceeds of US$25.0 million. Euro Pacific Canada Inc. and Roth Capital Partners, LLC acted as Joint Book-Running Managers for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as Lead Manager.
Neptune Announces Pricing of US$25 Million Offering of Common Shares
GlobeNewswire - Fri Feb 28, 7:34AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (Nasdaq:NEPT) (TSX:NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has priced an underwritten public offering of 10,000,000 newly issued common shares at a public offering price of US$2.50 per share.
Neptune Announces Proposed Offering of Common Shares
CNW Group - Thu Feb 27, 3:59PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission ("SEC") and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering.
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Neptune Appoints John Moretz as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Tue Feb 18, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces the appointment of John Moretz as special advisor to its Board of Directors. Mr. Moretz has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholders approval.
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec") that would resolve the International Trade Commission ("ITC") investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
AFET Ends Seed Banking Empowerment for Farmers
by Ebrima Bah - All Africa Global Media - Wed Jan 15, 8:02AM CST
The Association of Farmers, Educators and Traders (AFET) and Fandema has ended a twenty-day workshop on leadership and good governance for cooperative members and managers of certified seed growers in the provincial parts of The Gambia.
Neptune Reports Third Quarter Results and Provides Update on Action Plan to Resume Operations
GlobeNewswire - Tue Jan 14, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces its consolidated financial results for the three and nine-month periods ended November 30, 2013 and provides update on action plan to resume operations.
Neptune Receives New Food Raw Material Certification in China
GlobeNewswire - Thu Jan 09, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces that it has received "New Food Raw Material" certification in China. Neptune is now able to sell its krill oil nutraceutical products in China, including its premium krill oil, NKO, as well as its Eco krill oil "EKO(TM)". No quality or safety concerns were found by China's National Health and Family Planning Commission, which attests to the strength of Neptune's products.
Antelope Audio Zodiac Platinum DSD DAC/Headphone Amp Debuts at CES, Setting New Standard for Accuracy, Transparency, Imaging and Dynamics
PR Newswire - Tue Jan 07, 11:00AM CST
Leading digital audio manufacturer Antelope Audio [CES: Venetian, suite 29-227] introduces its new Zodiac Platinum DSD DAC/headphone amplifier during the 2014 Consumer Electronics Show (CES) in Las Vegas. The Zodiac Platinum, features a unique 256X upsampling mode where DSD64 and DSD128 are upsampled to DSD256, thereby releasing the true potential of DSD - delivering new standards in accuracy, transparency, imaging, and dynamics. The new DSD DAC ships with an entirely new, second-generation Voltikus power supply and an elegant aluminum remote control.
Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 07, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) will be holding a conference call on Wednesday January 15, at 9:00 am ET to present its results for the third quarter ended November 30, 2013. The Company will also be providing an update on the status of its previously disclosed action plan to resume operations and supply customers.
Neptune Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently.
Neptune, Acasti and Enzymotec Sign Settlement Term Sheet Resulting in Stay of ITC Investigation for 30 Days
GlobeNewswire - Wed Dec 18, 7:59AM CST
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that on December 16, 2013, the Administrative Law Judge presiding over the pending International Trade Commission (ITC) Investigation involving Neptune and Acasti; and Enzymotec Ltd., and Enzymotec USA, Inc. (collectively, "Enzymotec") granted the parties' joint motion to stay the proceedings for thirty days. The investigation was instituted earlier this year by Neptune and Acasti in a complaint filed with the ITC alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players.
Enzymotec Ltd. Announces Signing of Settlement Term Sheet
GlobeNewswire - Wed Dec 18, 7:01AM CST
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec"), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced today that it signed a term sheet on December 16, 2013 with Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) ("Neptune") and Acasti Pharma Inc. ("Acasti") memorializing the terms of a settlement among the parties. The term sheet is confidential and the settlement is subject to negotiation and execution of a final written settlement agreement. The on-going U.S. International Trade Commission ("ITC") investigation brought against Enzymotec by Neptune and Acasti has been stayed.
